Skip to main content
. Author manuscript; available in PMC: 2020 Nov 28.
Published in final edited form as: Cancer Lett. 2019 Sep 3;465:24–35. doi: 10.1016/j.canlet.2019.08.018

Figure 6. NK cells are required to control PGRN-regulated B16-F10 growth.

Figure 6.

(A-B) NK cells were depleted in B16-F10 and B16-F10/Grn−/− tumor-bearing mice by using anti-NK1.1 monoclonal antibody. The NK cell depletion in tumor was confirmed by NK1.1+ CD3− staining gated on CD45+ cells. (C) Tumor volume was measured every two days starting day 10. n=5 mice per group. Data are presented as mean ± SD (* P < 0.05, **P < 0.01, and *** P < 0.001 by Student t test). (D) B16-F10 and Grn−/− cells were injected subcutaneously and treated with 50 μg of anti-CD8α antibody. Tumor growth were measured from day 10 onward. Data are presented as mean ± SD (**P < 0.01 by Student t test).